Friday, June 10, 2016 3:23:11 PM
A Randomised, Double-blind, Three-arm, Parallel-group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of M923 (a candidate biosimilar of adalimumab), versus US-sourced Humira and EU-sourced Humira in Healthy Subjects, EULAR 2016
http://www.momentapharma.com/docs/poster_EULAR-2016-Baxalta-M923-final.pdf
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
